Tag Archives: resistance

Scientists look for new antimicrobials and urge government incentives

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

Photo: CDC/ Melissa Dankel

Researchers are looking to old drugs, plants and viruses in a race to find new ways to kill disease-causing microbes before they become resistant to all existing pharmaceuticals, but their work will flounder if the federal government can’t figure out how to incentive companies to turn their work into commercially viable drugs. Continue reading

Panel to look at challenges of fighting superbugs

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

Since antibiotics were widely introduced in the mid 1940’s, scientists warned of microbes’ innate ability to evolve and develop resistance. People were cautioned to be judicious with antimicrobials, because overuse could breed “superbugs,” germs resistant to most or all antibiotics.

Indeed, microbes have developed resistance to virtually every new class of antibiotics introduced. Up until the 1980s, however, most pharmaceutical companies kept developing new antibiotics. When a drug developed resistance, there was a new one in the development pipeline that could take its place. Continue reading

Consider the business angle when covering antibiotic resistance

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

Photo: NIAID via Flickr

In early October, the U.S. Food and Drug Administration approved Paratek Pharmaceuticals’ new antibiotic Nuzyra, which kills bacteria associated with skin and lung infections.

The approval was notable because there are so few new antibiotics coming onto the market, , says journalist Maryn McKenna in Wired magazine, largely because most drug companies don’t think antibiotics — which have wiped out the threat of many infectious diseases — to be worth the investment.

The problem is a unique business and policy dilemma for society. Continue reading

New CDC antibiotic resistance map is a potential source for story ideas

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

Staphylococcus aureus

Looking for a local angle to cover antibiotic resistance?

Reporters can find potential stories by looking at the Centers for Disease Control and Prevention’s newly released antibiotic resistance investment map which provides details on superbug cases in states and CDC efforts to contain their spread. Continue reading

Localize the story of the latest superbug’s U.S. arrival – for a long time to come

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Image via CDC

Image via CDC

The latest news about the arrival in the U.S. of a deeply concerning “superbug” justifiably injected alarm into the headlines recently.

It was not actually a new bacteria that arrived but the “dreaded gene mcr-1,” a mutation which “confers protection against colistin, the last remaining antibiotic that works against a broad family of bacteria that have already acquired resistance to all the other antibiotics used against them,” as AHCJ board member Maryn McKenna described in her piece at her Germination blog at National Geographic. Continue reading